K Studies in which drug dose is titrated on the basis of the urine albumin level (or change in GFR) are needed. K Studies on the effects of non-dihydropyridine calcium- channel blockers on long-term outcomes are needed. K Prospective studies of add-on therapy (consisting of thiazides, aldosterone antagonists, or DRIs) and reduc- tion of sodium chloride intake on the effects of ACE-Is or ARBs in patients with diabetes and CKD are encouraged. K Prospective studies of the combination of ACE-Is and ARBs in patients with diabetes and CKD are encouraged. K Prospective studies of different target BP levels stratified by GFR are encouraged. DISCLAIMER While every effort is made by the publishers, editorial board, and ISN to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contribu- tor, copyright holder, or advertiser concerned. Accordingly, the publishers and the ISN, the editorial board and their respective employers, office and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer s own published literature. SUPPLEMENTARY MATERIAL Supplementary Table 37. Evidence profile of RCTs examining the effect of ACEI or ARB vs. placebo in patients with CKD and DM. Supplementary Table 38. RCTs examining the effect of ACEI or ARB vs. placebo in patients with CKD and DM [categorical outcomes]. Supplementary Table 39. 